Screener
Cytokinetics CYTK SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 28,624 | 66,769 | 47,979 | 68,348 |
| Operating expenses: | ||||
| Research and development | 97,807 | 110,138 | 193,332 | 208,400 |
| Selling, general and administrative | 104,397 | 65,721 | 209,293 | 123,090 |
| Cost of goods sold | 2,731 | — | 2,891 | — |
| Collaboration cost of revenues | 2,861 | 2,416 | 5,253 | 3,995 |
| Total operating expenses | 207,796 | 178,275 | 410,769 | 335,485 |
| Operating loss | (179,172) | (111,506) | (362,790) | (267,137) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's SG&A?
- Cytokinetics (CYTK) reported SG&A of $104.4M in Q2 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Cytokinetics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude